Outlook: Remimazolam’s commercial prospects in sight
Paion is at an advanced stage in developing its ultra-short-acting sedativeremimazolam in pivotal US studies in procedural sedation. Paion has
launched the Phase III European study in lead indication general
anaesthesia, focusing on efficacy and safety vs standard of care. Paion is
evaluating its commercial options in the US, Europe and Japan. We have
updated our base case assumption, adding milestones for a post-approval
deal scenario. This leads us to raise our valuation to €224m from €176m.
Paion is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focusing on developing and commercializing drugs to be used in out-patient and hospital-based anesthesia, sedation and critical care services. Co.'s key compound is Remimazolam, an intravenous ultra short-acting and controllable anesthetic/sedative drug candidate in advanced stages of development for use in procedural sedation and general anesthesia.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.